drugset / Trial / NCT02216266
Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery
Phase 3
Unknown
120 enrolled
PD Dr. Bertram Scheller
Dr. Franz Köhler Chemie GmbH (study medication and labeling) · collabGoethe University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluation if physostigmine reduces symptoms in patients who has developed a delirium in Intensive care after a surgery
Timeline
- Start
- 2014-04
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Physostigmine | Small molecule | 0.04 mg/kg | Intravenous |
| Comparator | Physostigmine | Small molecule | 24 mg | Intravenous |